MedPath

A clinical trial to study the effects of two drugs, metformin lotion and zinc oxide cream in patients with melasma, a type of facial pigmentatio

Phase 2
Conditions
Health Condition 1: L811- Chloasma
Registration Number
CTRI/2023/09/057901
Lead Sponsor
ITHYAMS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients of both genders above 18 years who were clinically diagnosed to have melasma

2.Patients willing to give a written informed consent

Exclusion Criteria

Before starting the study

1.Pregnant & lactating mothers

2.Patients on oral contraceptives, phenytoin

3.Patients with unrealistic expectations

4.Patients who are allergic to metformin

5.Patients on medications for melasma since at least 2 weeks for topical therapy, 1 month for systemic steroids, 3 months for cosmetic procedures such as laser, dermabrasion, or peels

6.Patients with co-morbidities-DM, SHTN, TB,CAD,EPILEPSY,BA, carcinomas, Renal dysfunction,

During Study

1.If patient develops side effects during the treatment

2.If patient wants alternate treatment during the study.

3.If patient wants to discontinue the treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in intensity of pigmentationTimepoint: 8 weeks after using medication
Secondary Outcome Measures
NameTimeMethod
Prevention of relapseTimepoint: 1 year
© Copyright 2025. All Rights Reserved by MedPath